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Mixed lineage kinases activate MEK independently
of RAF to mediate resistance to RAF inhibitors
Anna A. Marusiak1, Zoe C. Edwards1, Willy Hugo2,*, Eleanor W. Trotter1,*, Maria R. Girotti3,
Natalie L. Stephenson1, Xiangju Kong2, Michael G. Gartside4, Shameem Fawdar1, Andrew Hudson1,
Wolfgang Breitwieser5, Nicholas K. Hayward4, Richard Marais3, Roger S. Lo2 & John Brognard1
RAF inhibitor therapy yields significant reductions in tumour burden in the majority of
V600E-positive melanoma patients; however, resistance occurs within 2–18 months. Here we
demonstrate that the mixed lineage kinases (MLK1–4) are MEK kinases that reactivate the
MEK/ERK pathway in the presence of RAF inhibitors. Expression of MLK1–4 mediates
resistance to RAF inhibitors and promotes survival in V600E-positive melanoma cell lines.
Furthermore, we observe upregulation of the MLKs in 9 of 21 melanoma patients with
acquired drug resistance. Consistent with this observation, MLKs promote resistance to RAF
inhibitors in mouse models and contribute to acquired resistance in a cell line model. Lastly,
we observe that a majority of MLK1 mutations identified in patients are gain-of-function
mutations. In summary, our data demonstrate a role for MLKs as direct activators of the
MEK/ERK pathway with implications for melanomagenesis and resistance to RAF inhibitors.
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T
he MLKs are MAP3Ks that regulate both the JNK and p38
MAPK pathways1. They directly phosphorylate MKK4/7 to
activate the JNK pathway and MKK3/6 to activate the p38
pathway in response to extracellular stimuli, leading to regulation
of a diverse array of cellular fates1. The MLK family contains
primary family members (MLK1–4, also known as MAP3K9,
MAP3K10, MAP3K11 and KIAA1804, respectively) that have Src
homology-3 (SH3) and CRIB (Cdc42/Rac-interactive binding
region) domains, and subfamily members (DLK, LZK and ZAK)
that lack these regulatory domains1. Previous studies have
indicated that one family member (MLK3) can activate the
RAF/MEK/ERK pathway; however, this activation appeared
independent of kinase activity and the authors suggested MLK3
acted as a scaffold to promote BRAF activation2,3. Consistent
with MLK3 regulating the RAF/MEK/ERK pathway, depletion of
endogenous MLK3 suppressed activation of the pathway, and
mice deficient in both MLK2 and MLK3 have reduced activation
of ERK in response to tumour necrosis factor stimulation2,4. In
addition, various studies suggest that MLKs are oncogenic and
mutations in this family of kinases have been observed in several
different cancers5–7. MAP3K9 (MLK1) has been identified as a
gene that is frequently mutated in melanoma (12 of 85, or 14%, of
melanoma patients evaluated had MLK1 mutations)8. Recently,
genetic alterations in MLKs have been reported by cancer
genomics data sets at a frequency of 15, 18 and 25% in cutaneous
skin melanomas9–12. However, the role of the MLKs in
melanomagenesis or resistance to RAF inhibitors has not been
investigated to date.
Aberrant activation of the MEK/ERK pathway leads to
tumorigenesis and the role of mutationally activated BRAF as a
driver of metastatic melanoma has been well established13–15.
Inhibition of mutationally activated BRAFV600E by vemurafenib
or dabrafenib results in significant clinical response rates in
V600E-positive metastatic melanoma patients. However, most
responses are incomplete (due to innate and adaptive drug
resistance) and, among those patients with objective tumour
responses, the median duration of response isB6 months due to
acquired drug resistance16,17. RAF inhibitor resistance can be
achieved through several mechanisms, including amplification or
mutations in upstream kinases (RAFs, MEK1 or COT kinases
or genetic alteration in upstream activators such as NRAS, KRAS
or epidermal growth factor receptor), ultimately leading to
reactivation of the MEK/ERK pathway in a majority of cases18–25.
Other mechanisms of resistance have also been identified,
including activation of the PI3K (phosphoinositide 3-kinase)/
AKT pathway23,26,27. Thus, there is an intense effort to further
understand mechanisms of innate, adaptive and acquired
resistance. Here we describe that MLK1–4 directly phospho-
rylate MEK and activate the MEK/ERK pathway independently of
RAF kinases. Moreover, we find that increased expression of
MLKs correlates with drug resistance in patients, implicating
their potential role as mediators of resistance to RAF inhibitors in
melanoma.
Results
MLKs are direct MEK kinases that activate the ERK pathway.
In an effort to evaluate the role of the mixed lineage family of
kinases (Fig. 1a) in regulating downstream signalling pathways,
we overexpressed WT (wild type), KD (kinase dead) and con-
stitutively active MLK1–4 in HEK293T cells and assessed mito-
gen-activated protein kinase (MAPK) pathway activation.
Exogenous expression of MLK1–4 resulted in activation of
MKK4, MKK7 and the JNK pathway (Fig. 1b). We also observed
that the MLKs are robust activators of the MEK/ERK pathway
and this requires a catalytically competent kinase domain
(Fig. 1b). Activation of the MEK/ERK pathway was enhanced by
expression of a constitutively active MLK3 and MLK4b (Fig. 1b),
where a proline residue is mutated to an alanine (referred to as
P469A for MLK3 and P491A for MLK4b hereafter). This muta-
tion results in a constitutively active MLK mutant, by relieving
autoinhibitory binding of this conserved proline to the SH3
domain1. Homologous mutations in MLK1 and MLK2 did not
increase pathway activation, indicating that MLK1/2 are regulated
in a unique manner and autoinhibition may occur by binding to
other carboxy-terminal regions of the kinases (Fig. 1b). To
confirm that activation of the MEK/ERK pathway was dependent
on MLK kinase activity, rather than scaffolding effects, we
generated constitutively active KD mutants for MLK3 and MLK4
that would serve as an open scaffold, but lack kinase activity (KD/
P469A or KD/P491A, respectively). Both mutants were unable to
activate the MEK/ERK pathway (Fig. 1c), indicating a functional
kinase domain is required for activation of the ERK pathway.
Evaluation of other distant MLK family members and another
MAP3K indicated that this function is specific to MLK1–4, as
exogenous expression of LZK, ZAKb or ASK1 did not alter
signalling through the MEK/ERK pathway (Fig. 1d). This implies
that regulatory domains present on MLK1–4, such as the SH3
domain or the CRIB domain, are required for regulation of the
MEK/ERK pathway.
To determine the mechanism used by MLK1–4 to activate the
MEK/ERK pathway, we overexpressed the MLKs in HEK293T
cells and treated the cells with a pan-RAF inhibitor (L779450) or
a MEK inhibitor (U0126). MLK1–4 activated the MEK/ERK
pathway in the presence of the RAF inhibitor but not the MEK
inhibitor, indicating that MLKs directly phosphorylate MEK
(Fig. 2a and Supplementary Fig. 1a in H157 cells; note both
L779450 and U0126 blocked EGF-stimulated ERK activation in
cells, Supplementary Fig. 1b). These results were verified with
additional RAF and MEK inhibitors, sorafenib and AZD6244,
respectively (Supplementary Fig. 1c,d). To assess whether the
MLKs directly phosphorylate MEK, we performed in vitro kinase
assays using purified inactive MEK1. Immunoprecipitated full-
length MLK1–4 directly phosphorylated KD MEK1 and the
activity of the kinases was not altered by the presence of RAF or
MEK inhibitors (Fig. 2b and Supplementary Fig. 1e). To rule out
the possibility that other kinases could co-precipitate with MLKs
and phosphorylate MEK1, we used purified GST-MLK4 kinase
domain in an in vitro kinase assay and observed that the MLK4
kinase domain directly phosphorylated MEK1 and was not
inhibited by RAF or MEK inhibitors (Fig. 2c). This is consistent
with our previous report that purified GST-MLK1 kinase domain
can directly phosphorylate KD MEK1 in vitro28.
MLKs reactivate the ERK pathway in melanoma cells. Based on
our proposed mechanism whereby MLKs can activate the MEK/
ERK pathway in a manner independent of the RAF kinases, we
sought to determine whether MLKs may mediate reactivation of
this pathway in the presence of RAF inhibitors in V600E-positive
melanoma cells. We transiently expressed MLK1–4 and their
respective KD mutants in A375 cells and treated the cells with
vemurafenib (PLX4032). We observed that expression of MLKs
reactivated the MEK/ERK pathway in the presence of vemur-
afenib in a kinase-dependent manner (Supplementary Fig. 2a).
Next, we generated melanoma cell lines (both with V600E
mutations: A375 and A2058) where MLK expression could be
induced in response to tetracycline. Vemurafenib effectively
inhibited phosphorylation of MEK and ERK in these melanoma
cell lines, while induced expression of MLK1–4 promoted reac-
tivation of the MEK/ERK pathway despite the presence of
vemurafenib (Fig. 3a,b). Treatment of cell lines with MEK
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Figure 1 | MLK1–4 are upstream regulators of the ERK pathway. (a) Schematic representation of MLKs domains (SH3, Src homology-3 domain;
LZ, leucine-zipper; CRIB, Cdc42/Rac-interactive binding region). (b) HEK293T cells were transiently transfected with Flag- or HA-tagged MLK1–4 WT
(wild type); P496A–MLK1, P450A–MLK2, P469A–MLK3 and P491A–MLK4b; KD (kinase dead) (D294A–MLK1 (DFG motif), K125M–MLK2,
K144M–MLK3 and K151M–MLK4b), or EV (empty vector) control. After 48 h, cells were lysed and analysed by western blotting. (c) Activation of the
MEK/ERK pathway is dependent on MLK kinase activity. HEK293T cells were transiently transfected with HA-MLK3 or Flag-MLK4b constructs
or EV. Cell lysates were analysed by western blotting. (d) LZK, ZAKb and ASK1 activate JNK but not MEK/ERK. HEK293Tcells were transiently transfected
with EV or Flag-LZK WT or KD (K195M), HA-ZAKb WT or KD (K45M), HA-ASK1 WT or KD (K709M). After 48 h, cells were lysed and analysed by
western blotting. HA- or Flag-tagged MLK3 WT is a positive control. All results are representative of three independent experiments.
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Figure 2 | MLK1–4 phosphorylate MEK in the presence of RAF inhibitors. (a) HEK293T cells were transiently transfected with Flag- or HA-tagged
MLK1–4 constructs or EV (empty vector) control. Cells were treated with 5mM L779450, 5mM U0126 or DMSO for 1 h and lysed. Cell lysates were
analysed by western blotting. (b) MLK1–4 are MEK1 kinases. Flag- or HA-tagged MLK1–4 WT, KD or EV control were transiently transfected in HEK293T
cells. Forty-eight hours later, cells were treated with 1 mM PLX4032 (vemurafenib), 5 mM L779450 or DMSO for 1 h before lysis. MLK1–4 were
immunoprecipitated and subjected to a kinase assay with kinase-inactive MEK1. Control sample does not include any cell lysate. (c) Kinase-inactive MEK1
and purified GST-MLK4b kinase domain (isolated from baculovirus-infected insect cells) were subjected to in vitro kinase assay in the presence or
absence of inhibitors: 1mM PLX4032 (vemurafenib), 5 mM L779450 or 5 mM U0126. All results are representative of three independent experiments.
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inhibitors prevented phosphorylation of the pathway even
with the expression of MLKs, confirming that the MLKs
directly activate MEK (Supplementary Fig. 2b). To further
validate that MLK1–4 activate the MEK/ERK pathway indepen-
dently of RAF kinases we used PB04, a non-paradox-inducing
RAF inhibitor that does not promote transactivation of RAF
isoforms29. Expression of MLK1–4 reactivated the MEK/ERK
pathway in the presence of PB04 in the A375 and A2058
melanoma cell lines, confirming that MLKs directly phospho-
rylate MEK rather than act as a scaffold to promote RAF-
mediated activation of the MEK/ERK pathway (Fig. 3c and
Supplementary Fig. 2c).
To assess whether the V600E mutant allele of BRAF was
required for MEK phosphorylation by the MLKs in melanoma
cells, we depleted A375 cells of BRAF using small interfering
RNA (siRNA) and observed that MLK1–4 induction was still able
to activate the MEK/ERK pathway, indicating that the BRAFV600E
allele is dispensable for MLK-mediated activation of MEK in
these cells (Fig. 3d). Consistent with these being RAF-indepen-
dent effects, the MLKs could promote activation of the MEK/ERK
pathway in the presence of the pan-RAF inhibitor (L779450),
ruling out the possibility that MLKs mediate their effects through
ARAF or CRAF (Supplementary Fig. 2d,e).
To determine whether MLKs can promote resistance to
vemurafenib in terms of cell survival, we assessed cell viability
by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay. Importantly, expression of each MLK isoform
significantly increased survival in melanoma cells treated with
vemurafenib (Fig. 4a,b). The reactivation of the MEK/ERK
pathway by expression of MLKs is complete for MLK1 in A375
cells and MLK3 in A2058 cells, whereas MEK/ERK phosphoryla-
tion is only partially restored by MLK2–4 in A375 cells and
MLK1, MLK2 and MLK4 in A2058 cells (Fig. 3a,b). Nevertheless,
this level of pathway reactivation is sufficient to promote MLK-
mediated survival in the presence of vemurafenib in both
melanoma cell lines (Fig. 4a,b). To verify the survival advantage
conferred by the MLKs in the presence of vemurafenib, we
monitored poly (ADP-ribose) polymerase (PARP) and caspase-3
cleavage, indicators of apoptosis, and we assessed the level of
XIAP, a member of the inhibitors of apoptosis family of proteins.
Induced expression of all four MLKs abrogated the reduction in
XIAP levels, as well as the cleavage of PARP and caspase-3, in
response to vemurafenib in the A375 cells, suggesting that the
MLKs can mediate resistance to vemurafenib-induced apoptosis
(Fig. 4c). Lastly, we verified the MLK-mediated resistance to
vemurafenib using an annexin V assay and found that
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Figure 3 | MLK1–4 reactivate the MEK/ERK pathway in V600E-positive melanoma cells independently of the RAF kinases. (a,b) Expression of
MLKs in A375 and A2058 cell lines was induced by addition of tetracycline. After 24 h, cells were treated with 1 mM PLX4032 (vemurafenib) or DMSO for
1 h, lysed and analysed by western blotting. (c) Expression of MLK1–4 in A375 cells was induced by addition of tetracycline. After 24 h, cells were
treated with 1mM PB04 or DMSO for 1 h, lysed and analysed by western blotting. (d) Expression of MLKs reverses the effect of BRAF knockdown on
activation of the MEK/ERK pathway. A375 cells were transfected with siRNA against BRAF or control siRNA. After 24 h, expression of MLKs was induced
by tetracycline. Cells were lysed and analysed by western blotting. All results are representative of three independent experiments.
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significantly fewer cells underwent apoptosis when MLKs were
expressed (Fig. 4d).
To investigate whether activation of the JNK pathway is
important for the survival effects mediated by MLKs, we treated
melanoma cells with vemurafenib and a JNK inhibitor
(SP600125). Addition of SP600125 effectively inhibited MLK-
induced activation of the JNK pathway (monitored by decreases
in c-Jun phosphorylation), but did not affect resistance to
vemurafenib mediated by MLK1, 2 or 4 (Supplementary
Fig. 3a,b). For MLK3, treatment of cells with the JNK inhibitor
dramatically decreased the expression of MLK3 and the resistance
to vemurafenib mediated by MLK3 (Supplementary Fig. 3a,b).
MLK upregulation correlates with drug resistance in patients.
To assess whether alterations in MLKs correlated with resistance
to RAF inhibitor therapy, we analysed mRNA expression of
MLK1–4 from the data set recently published by Rizos et al.30
The authors performed gene expression analysis on matched
pretreatment and disease progression biopsies from 21 metastatic
melanoma patients30. All patients were BRAFV600-positive and
treated with RAF kinase inhibitors, vemurafenib or dabrafenib30.
Here we evaluated mRNA expression of MLK1–4 before and
during disease progression in 29 pair-wise comparisons in 21
patients (Fig. 5a). We detected upregulation of MLK1–3 in 9 of 21
(42.9%) patients, or in 12 of 29 (41.4%) disease progressive
tumours (versus their patient-matched baseline; Fig. 5a). Multiple
MLKs were upregulated at the sites of disease progression with
respect to their baseline melanoma in five patients, whereas a
single MLK was upregulated in four patients (Fig. 5a). Ten disease
progression sites (out of 12) that displayed enhanced expression
of MLK1-3 showed reactivation of the MAPK pathway
(Supplementary Table 1)30. In addition, five disease progression
sites lacked other known mechanisms of acquired BRAF inhibitor
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resistance (Supplementary Table 1)30. Three melanoma patients
displayed upregulation of MLKs together with COT kinase
upregulation (Fig. 5a). COT kinase upregulation has previously
been described as a mechanism of resistance to RAF inhibitors in
melanoma31; thus, we used it as a positive control reference in our
study. We noted that the ranges of upregulation of MLK1–3 (1.5-
to 3.3-fold increase) are similar to that of COT kinase (1.6- to 2.4-
fold increase), strongly indicating that the upregulation events
that we observe are biologically relevant (Fig. 5a). In summary,
these clinical data suggest that MLKs are used to promote
resistance to RAF inhibitor therapy in patients.
Expression of MLKs promotes resistance in mouse models. To
assess whether MLKs could promote resistance in a xenograft
mouse model, we injected mice with A375 cells that had stably
incorporated, doxycycline-inducible MLK1. All mice formed
engrafted tumours within 18 days, at which point we commenced
treatment with either vehicle control or PLX4720 (a vemurafenib
analogue). Expression of MLK1 was induced 5 days after the start
of PLX4720 treatment to assess acquired resistance (group C) or 2
days before the first treatment with the drug to evaluate de novo
resistance (group D) (Fig. 5b). PLX4720 treatment significantly
suppressed tumour growth (group B), while MLK1 induction
decreased the overall tumour response to PLX4720 in both
models of resistance, acquired and de novo (Fig. 5b). Group C,
representing acquired resistance, showed initial response to
PLX4720 treatment until MLK1 expression was induced by
administration of doxycycline on day 8, and following doxycy-
cline treatment the tumours started gradually increasing in size
(Fig. 5b). Group D, representing de novo resistance, did not show
initial response to PLX4720 due to MLK1 expression before the
start of the treatment (Fig. 5b). Analogous results were observed
with mouse xenografts using MLK3-inducible A375 cells
(Supplementary Fig. 4). This indicates that increased expression
of MLKs can promote resistance to RAF inhibitors in vivo, which
is consistent with the observation that increased expression of
MLKs correlates with resistance at sites of disease progression in
patients (Fig. 5a). We also observed that MLK1 or MLK3
induction alone (group E) reduced tumour growth compared
with the vehicle-treated group (group A) (Fig. 5b and
Supplementary Fig. 4). This is likely to be due to sustained acti-
vation of the JNK pathway, which can promote cell death, and in
the absence of BRAFV600E inhibition the JNK pathway will be the
primary pathway activated downstream of overexpressed MLK1
or MLK3. Our data indicate that the MLKs will promote mela-
noma cell survival when BRAFV600E is inhibited and melanoma
cells seek other mechanisms to reactivate the MEK/ERK pathway.
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MLK2 promotes resistance to vemurafenib in cell line model.
To test whether endogenous MLKs mediate resistance, we estab-
lished two drug-resistant V600E-positive melanoma cell lines,
MDA-MB-435 (ref. 32) and A375, by chronic treatment with 1mM
vemurafenib. These cells were maintained in the presence of the
drug and showed sustained phosphorylation of ERK when
compared with the parental cell line (Fig. 6a, lane 1, 4, 7 and
Supplementary Fig. 5a). To determine whether MLKs were med-
iating resistance, we used siRNA to deplete MLK1–4 in both
resistant cell lines. We observed that depletion of MLK2, but not
MLK1, 3 or 4, in MDA-MB-435 cells led to decreased MEK/ERK
pathway activation (Fig. 6a and Supplementary Fig. 5b).
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Interestingly, MLK2 depletion modestly inhibited MEK phosphor-
ylation and robustly inhibited phosphorylation of the downstream
target ERK, which probably reflects the presence of more active
ERK phosphatases compared with MEK phosphatases (Fig. 6a). We
were unable to detect endogenous MLK2 by western blotting due to
low-quality antibodies; thus, knockdown was assessed by reverse
transcription–PCR (RT–PCR) (Fig. 6a). Suppression of ERK path-
way activation due to MLK2 depletion correlated with a reduction
in cell viability in resistant MDA-MB-435 cells (Supplementary
Fig. 5c). Depletion of MLKs from drug-resistant A375 cells did not
alter MEK/ERK pathway activation, suggesting that these cells use
different mechanisms to reactivate ERK (Supplementary Fig. 5d).
This result is in line with previous reports of alternative resistance
mechanisms described in the A375 cell line21.
Gain-of-function mutations in MLK1 in melanoma patients.
MAP3K9 (MLK1) has been identified as a gene that is frequently
mutated in melanoma8. Fourteen per cent (12 of 85) of melanoma
patients evaluated by this study had MLK1 mutations, including
6% (5 of 85) of patients that had both BRAFV600E and MLK1
mutations8. The authors characterized a truncation mutation,
W333*, as a loss-of-function mutation, and it was proposed that
MLK1 acts as a tumour suppressor in melanoma; however, this
mutation was not confirmed in the primary tumour sample8.
Here we determined the functional consequences of other MLK1
mutations from melanoma patients that were identified by Stark
et al.8 We observed that several of these mutations (including
recurrent mutations) were gain-of-function (GOF) towards the
MEK/ERK pathway when compared with WT MLK1 (Fig. 6b). In
total, 10.6% (9/85) of melanoma patients have GOF mutations in
MLK1; however, some mutations were neutral or loss-of-function
(Supplementary Fig. 5e). To provide insight into the molecular
mechanism that causes the D176N mutation to activate MLK1,
we performed structural analysis, and based on a comparison
between the homology modelled D176N mutant and the MLK1
crystal structure, we observe the change from Asp to Asn results
in loss of a polar contact, specifically the Arg at position 303
(Fig. 6c). Loss of this polar contact between Asp 176 and Arg 303
could cause destabilization, allowing the ATP binding site to be
more open and shifting the equilibrium of the kinase into a more
active conformation (Fig. 6d). The presence of GOF mutations in
MLK1 in V600E-positive patients suggests these patients could be
predisposed to de novo resistance. These data emphasize the
importance of MLK1 in melanoma as a potential drug target.
Discussion
Our data demonstrate that MLK1–4 are MEK kinases that are
able to directly phosphorylate MEK to activate the MEK/ERK
pathway independently of the RAF kinases. These data provide a
new layer of complexity in regards to MAPK signalling; we have
shown that the MLKs are not only able to phosphorylate MKK4/7
to regulate the JNK pathway, but also MEK1/2 to regulate the
ERK pathway. It was previously reported that MLK3 acts as a
scaffold for BRAF to activate the MEK/ERK pathway; however,
our data demonstrate that the MLKs act directly at the level of
MEK, and through phosphorylation of MEK can activate ERK.
Interestingly, we only observed this for MLK1–4, while less
related MLK family members such as LZK and ZAK were unable
to activate the MEK/ERK pathway on overexpression. This
suggests that domains specific to MLK1–4, such as the SH3
domain, are likely to be important in mediating scaffolding
interactions that will dictate MLK regulation of the ERK
pathway compared with the JNK pathway. It will be important
to fully understand what dictates pathway specification by this
understudied family of kinases. Much remains to be determined
regarding the nature of when and how the MLKs regulate the
MEK/ERK pathway and future studies should reveal exciting
revelations regarding the molecular mechanisms important for
differential regulation of downstream components.
From our observation that the MLKs could phosphorylate
MEK, we then aimed to determine whether MLKs could facilitate
resistance to vemurafenib. Resistance generally occurs through
reactivation of the MEK/ERK pathway, although activation of the
PI3K/AKT pathway by receptor tyrosine kinase upregulation18–24
or by genetic mechanisms contributes to MAPK-independent
survival18–24,27. Reactivation of the MEK/ERK pathway can be
achieved by increased expression or mutational activation of the
RAF kinases, MEK1, or upstream activators (such as NRAS,
KRAS, platelet-derived growth factor receptor, epidermal growth
factor receptor or MET-ligand induced activation)20,24,25,33.
Expression of the p61 BRAFV600E splice variant shows enhanced
dimerization rendering a subset of melanoma patients resistant to
vemurafenib19,34. In addition, kinases that act independently of
RAF to phosphorylate MEK have the potential to mediate
resistance, such as COT kinase31,33. Our study identifies an
additional novel mechanism whereby MLK1–4 can reactivate
the MEK/ERK pathway independently of RAFs (Fig. 6e). We
have shown that expression of MLKs promotes resistance to
RAF inhibitors (including vemurafenib) via direct MEK
phosphorylation in melanoma cell lines, in mouse models of
resistance and in a cell line model of resistance. Importantly,
increased expression of MLK1-3 occurs at sites of disease
progression across patients treated with RAF inhibitors, further
confirming the role of MLKs in mediating resistance to RAF
inhibitor therapy. Upregulation of MLKs was detected in several
drug-resistant tumours that lack other known mechanisms of
acquired resistance (Supplementary Table 1)30, implying that
increased expression of MLKs is sufficient to reactivate the MAPK
pathway in those tumours. On the other hand, a subset of drug-
resistant tumours display upregulation of MLKs together with
expression of BRAF splice variants (Supplementary Table 1)30, a
previously described mechanism of resistance19,34. This suggests
that multiple mechanisms might contribute to reactivation of the
MAPK pathway and tumour survival. Alternatively, the
upregulation of MLKs may have a transient effect on MAPK
pathway reactivation until further mechanisms of drug resistance
are developed. It is currently unclear how early MLK
overexpression occurs subsequent to the initiation of RAF-
targeted therapies. Delineation of such temporal expression
dynamics may provide additional insight into the roles of these
MEK kinases in early-adaptive versus late-acquired resistance
(explaining incomplete initial responses versus subsequent clinical
relapses).
Finally, we have characterized several MLK1 mutations
observed in melanoma patients to be GOF mutations. The
presence of intermediate-activating mutations in MLK1 suggests
that MLK1 mutations could predispose V600E-positive patients
to de novo resistance (Fig. 6e). Further studies will be aimed at
determining whether GOF mutants of MLK1 can enhance
melanomagenesis, suggesting MLK1 may be a melanoma
oncogene. In conclusion, elucidating mechanisms of resistance
to RAF inhibitors in melanoma patients is essential to achieve
long-term progression-free survival and further understand the
basic biology of this disease. Here we have identified the MLKs as
a family of kinases that can directly phosphorylate MEK to
mediate resistance to RAF inhibitors.
Methods
Cell lines and reagents. HEK293T and H157 cells were cultured in DMEM
supplemented with 10% FCS, 1% penicillin/streptomycin and 2mM L-glutamine.
A375, A2058 and MDA-MB-435 cells were cultured in RPMI supplemented with
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10% FCS, 1% penicillin/streptomycin and 2mM L-glutamine. The H157 non-small-
cell lung carcinoma and A2058 cell lines were kind gifts from Dr Phillip
Dennis and Dr Geoff Margison. All other cell lines were obtained from ATCC.
PLX4032 (vemurafenib), AZD6244 and sorafenib were purchased from Selleck
Chemicals. L779450 and SP600125 were obtained from Merck. U0126 was
purchased from Cell Signaling Technology. PB04 was provided by Dr Gideon
Bollag (Plexxikon Inc.). All inhibitors were dissolved in dimethyl sulphoxide
(DMSO) and stored at  20 C.
Generation of tetracycline-inducible cell lines. Parental A375 and A2058 mel-
anoma cell lines were used to generate cells with tetracycline-inducible expression
of MLKs. MLK1–4 plasmids (cloned into pLenti/TO/V5-DEST vector) and
pLenti3.3/TR (for tetracycline repressor expression) were transfected into 293FT
cells using Lipofectamine2000 to generate lentiviral stock. Cells were transduced
with lentiviral stocks and cell lines generated by antibiotic selection (Blasticidin
(Invitrogen) and Geneticin (Gibco)). Tetracycline (Invitrogen) was used to induce
expression of MLKs.
Generation of vemurafenib-resistant cell lines. The MDA-MB-435 and A375
drug-resistant cell lines were generated by treating parental cells with 1 mM
vemurafenib. After about 1 month, colonies of resistant cells were trypsinized,
picked into 12-well plates and expanded as necessary on reaching confluency. At
each stage, medium was removed daily and replaced with fresh medium containing
vemurafenib. For all experiments, 1 mM vemurafenib was added to resistant cells
when seeding and again after 24 h where appropriate.
Protein lysate preparation and immunoblots. Forty-eight hours after transient
transfection, cells were treated with inhibitors or DMSO vehicle control for the
appropriate time before lysis with Triton X-100 lysis buffer (Cell Signaling
Technology) supplemented with protease inhibitor tablet (Roche). Primary anti-
bodies: p-ERK1/2 (T202/Y204), p-MEK (S217/221), ERK1/2, MEK, p-MKK4
(S257/T261), p-MKK7 (S271/T275), MKK4, p-JNK (T183/Y185), JNK, MLK1,
PARP, XIAP, cleaved caspase-3 (Cell Signaling Technology), MLK2, MLK3
(Epitomics), MLK4 (Bethyl), HA (Covance), Tubulin, Flag M2 (Sigma) and BRAF
(Santa Cruz). Tubulin antibody was used at 1:10,000 dilution and Flag M2 at
1:5,000 dilution. All other antibodies were used at 1:1,000 dilution. Uncropped
scans of the most important immunoblots are shown in Supplementary Fig. 6.
Plasmids and transfections. MLK1 in entry vector was purchased from OriGene.
MLK2, 3 and 4b were obtained from GeneCopoeia as shuttle clones. MLKs were
cloned into Flag- or HA-tagged destination vectors. ASK1 and ZAKb (Addgene)
were cloned into Flag- or HA-tagged destination vectors. LZK complementary
DNA was prepared from RNA extracted from HEK293T cells, attB flanking
regions were added by PCR and the BP clonase reaction used to insert LZK into
pDONR221. Mutations were introduced using a Site-Directed Mutagenesis Kit
(Stratagene). HEK293T and H157 cells were transiently transfected using Attrac-
tene (Qiagen) according to the manufacturer’s protocol. A375 cells were trans-
fected using Lipofectamine2000 (Invitrogen) according to the manufacturer’s
protocol. DharmaFECT1 (Thermo Scientific) was used for siRNA transfections.
siRNA against BRAF (50-AAA GAA UUG GAU CUG GAU CAU-30) was obtained
from Thermo Scientific. MLK2 siRNA were purchased from Invitrogen (50-GGC
UUU GAG CAU AAG AUC A-30) and Santa Cruz (sc-39111). siRNA against
MLK1 were obtained from OriGene (50-ACCUUUGAAUAGAGUGUUAUCU
GGG-30) and Ambion (50-GACCAUCUUUCACGAAUAU-30), siRNA against
MLK3 were obtained from Thermo Scientific (J-003577-11) and Ambion (50-CGU
GAUCUCAAGUCCAACA-30), siRNA against MLK4 were obtained from Thermo
Scientific (50-GGAAAGAUGCUCAGAGAGAUU-30 and 50-AGGAGAAGCCCAA
GGUAAAUU-30).
Immunoprecipitation and kinase assays. Cells were seeded into six-well plates
and transiently transfected the next day. Forty-eight hours later, cells were treated
with inhibitors or DMSO and lysed with Triton X-100 lysis buffer (Cell Signaling
Technology). Cell lysates were incubated with anti-Flag M2 affinity gel (Sigma) for
2 h or rabbit HA antibody (Cell Signaling Technology) diluted 1:50 for 2 h followed
by incubation with protein A/G beads (Thermo Scientific) for 1 h. Beads were
washed with lysis buffer and kinase buffer (Cell Signaling Technology), and kinase
assay was performed in the presence of 200 mM ATP and kinase-inactive MEK1
purified from baculovirus-infected insect cells (Carna Biosciences), at 30 C for
30min. Following addition of 4 reduced SDS sample buffer, proteins were
resolved by SDS–PAGE and analysed by western blotting.
In vitro kinase assay. Human glutathione S-transferase (GST)-tagged MLK4
kinase domain expressed using baculovirus expression system (Carna Biosciences)
was incubated with kinase-inactive MEK1 (Carna Biosciences) in the absence or
presence of specific inhibitors. Kinase assay was performed with 200 mM ATP at
30 C for 30min. Following addition of 4 reduced SDS sample buffer, proteins
were resolved by SDS–PAGE and analysed by western blotting.
Cell proliferation and viability assays. Cells were seeded into 96-well plates and
tetracycline was added into the medium the following day. After 24 h, cells were
treated with inhibitors for 4 days. MTT Kit (Sigma) was used according to the
manufacturer’s instructions.
Annexin V and dead cell assay. Cells were seeded into 12-well plates and tet-
racycline was added the following day. After 24 h, cells were treated with PLX4032
for 2 days. Annexin V and Dead Cell Kit (Muse Annexin V and Dead Cell Reagent)
was used according to the manufacturer’s instructions and cells were analysed by
Muse Cell Analyzer.
Mouse xenografts and in vivo drug studies. All procedures involving animals
were approved by CRUK Manchester Institute’s Animal Welfare and Ethical
Review body in accordance with the Animals (Scientific Procedures) Act 1986 and
according to the guidelines of the Committee of the National Cancer Research
Institute35. Five- to six-week-old female nude mice were injected subcutaneously
with 5 106 MLK1-inducible A375 cells (ten mice per group). For MLK3-
inducible model, 5 106 A375 cells were injected subcutaneously into 8- to 10-
week-old female nude mice (three mice per group). Tumours were allowed to
establish, size matched and then the mice were randomly allocated to groups of ten
animals (three for MLK3 model). No blinding was used in the treatment schedules
for these studies. Based on literature precedents, groups of ten animals were used to
provide sufficient animals per cohort, to provide statistically significant data,
although keeping the number of animals used to a minimum. For MLK1
xenografts, treatment was by oral gavage daily with vehicle (5% DMSO, 95% water)
or PLX4720 45mpk and/or doxycycline. Tumour size was determined by caliper
measurements of tumour length, width and depth, and volume was calculated as
volume¼ 0.5236 lengthwidth depth (mm3). For MLK3 xenografts,
vemurafenib treatment was administered by daily gavage at a dose of 25mpk.
Doxycycline diet started on the same day as vemurafenib treatment or 5 days later.
Tumour formation was monitored every few days and tumour volume based on
caliper measurements was calculated by the formula: tumour
volume¼ (lengthwidthwidth)/2. Mice for both experiments were culled when
tumours reached max-permitted volume 1,200mm3 or after 5 weeks post injection
of A375 cells.
Microarray data. The mRNA expressions BRAFi samples are taken from the
microarray data set published by Rizos et al.30 (accession number GSE50509). They
obtained the total RNA from fresh-frozen melanoma samples from patients before
dabrafenib (Dab) or vemurafenib (Vem), and at the time of disease progression
(DP). The expression data was done on Illumina HumanHT-12 V4.0 Expression
BeadChip microarray, which we normalized using the normaliseIllumina function
in the beadarray R package. Significant expression alterations are defined by 50%
up- or downregulation in line with the earlier report of at least 1.5-fold upregulation
of COT kinase in two out of three BRAF inhibitor-treated patient samples31. In the
subset of patients with replicate data (P7-Pre, P8-Pre, P10-Pre, P11-Pre, P11-DP1-
Dab, P11-DP2-Dab, P13-Pre, P18-Pre and P24-Pre), the fold change is computed as
the fold change of the median expression value across the replicates.
Reverse transcription–PCR. RT–PCR was used to assess expression and siRNA
knockdown of MLK2 in resistant MDA-MB-435 cell lines. An RNeasy Mini Kit
(Qiagen) was used to extract RNA. RT–PCR was performed using a OneStep
RT–PCR Kit (Qiagen) according to the manufacturer’s protocol. The PCR
conditions were as follows: cDNA synthesis and predenaturation (1 cycle at 55 C
for 30min followed by 94 C for 2min); PCR amplification (30 cycles of denaturing
at 94 C for 15 s, annealing at 55 C for 30 s and extension at 68 C for 60 s) and a
final extension at 68 C for 5min. The PCR products were electrophoresed on 2%
agarose gels and visualized with Nancy-520 (Sigma) under ultraviolet light. All
primers were synthesized by Eurofins. Sequences of these primers are: MLK2
forward (50-GAACGTGAGATGGACATCGTGGAA-30), MLK2 reverse (50-AGGC
CTGGACTGTGATCTTATGCT-30), GAPDH forward (50-CCATGGAGAAGGC
TGGGG-30) and GAPDH reverse (50-GTCCACCACCCTGTTGCTGTA-30).
Statistical and structural analysis. For xenograft studies, MTT and annexin
V/7-AAD tests, statistical comparison of values was performed using the Student’s
t-test. The homology model of the MLK1 D176N kinase domain was created
using SwissModel36 using the MLK1 kinase domain as a template (PDB accession
code: 3DTC). Analysis of polar contacts was performed within PyMol v1.3.
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